Prelude Capital Management’s Regenxbio RGNX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $676K | Sell |
82,321
-30,199
| -27% | -$248K | 0.07% | 359 |
|
|
2025
Q1 | $805K | Buy |
+112,520
| New | +$805K | 0.06% | 304 |
|
|
2024
Q2 | – | Sell |
-21,565
| Closed | -$454K | – | 1354 |
|
|
2024
Q1 | $454K | Buy |
+21,565
| New | +$454K | 0.02% | 604 |
|
|
2020
Q4 | – | Sell |
-2,017
| Closed | -$56K | – | 1401 |
|
|
2020
Q3 | $56K | Hold |
2,017
| – | – | ﹤0.01% | 833 |
|
|
2020
Q2 | $74K | Buy |
2,017
+2,013
| +50,325% | +$73.9K | ﹤0.01% | 721 |
|
|
2020
Q1 | $0 | Sell |
4
-1,462
| -100% | – | ﹤0.01% | 1445 |
|
|
2019
Q4 | $60K | Buy |
+1,466
| New | +$60K | ﹤0.01% | 890 |
|
|
2019
Q2 | – | Sell |
-151
| Closed | -$9K | – | 1638 |
|
|
2019
Q1 | $9K | Buy |
+151
| New | +$9K | ﹤0.01% | 1095 |
|
|
2018
Q4 | – | Sell |
-200
| Closed | -$15K | – | 1689 |
|
|
2018
Q3 | $15K | Sell |
200
-9,125
| -98% | -$684K | ﹤0.01% | 1025 |
|
|
2018
Q2 | $669K | Buy |
9,325
+965
| +12% | +$69.2K | 0.04% | 329 |
|
|
2018
Q1 | $250K | Buy |
+8,360
| New | +$250K | 0.02% | 559 |
|
|
2017
Q4 | – | Sell |
-6,055
| Closed | -$200K | – | 1510 |
|
|
2017
Q3 | $200K | Buy |
6,055
+416
| +7% | +$13.7K | 0.02% | 589 |
|
|
2017
Q2 | $111K | Buy |
5,639
+3,308
| +142% | +$65.1K | 0.01% | 678 |
|
|
2017
Q1 | $45K | Buy |
+2,331
| New | +$45K | ﹤0.01% | 970 |
|